for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Abeona Therapeutics Inc

ABEO.OQ

Latest Trade

2.95USD

Change

0.00(0.00%)

Volume

186,625

Today's Range

2.84

 - 

2.96

52 Week Range

1.36

 - 

5.18

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.95
Open
2.86
Volume
186,625
3M AVG Volume
21.35
Today's High
2.96
Today's Low
2.84
52 Week High
5.18
52 Week Low
1.36
Shares Out (MIL)
83.70
Market Cap (MIL)
238.54
Forward P/E
-2.76
Dividend (Yield %)
--

Next Event

Abeona Therapeutics Inc Annual Shareholders Meeting

Latest Developments

More

Abeona Therapeutics Q1 Loss Per Share $0.52

Calpers Urges Abeona Therapeutics Shareholders To Vote For Proposal Requesting Majority Vote For Director Elections

Abeona Therapeutics Q4 Loss Per Share $0.30

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Abeona Therapeutics Inc

Abeona Therapeutics Inc. is a clinical-stage biopharmaceutical company developing novel gene therapies for life-threatening rare genetic diseases. The Company’s lead programs include ABO-102 (AAV-SGSH), an adeno-associated virus (AAV) based gene therapy for Sanfilippo syndrome type A (MPS IIIA) and EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB). It is also developing ABO-101 (AAV-NAGLU) for Sanfilippo syndrome type B (MPS IIIB), ABO-201 (AAV-CLN3) gene therapy for juvenile Batten disease (JNCL), ABO-202 (AAV-CLN1) for treatment of infantile Batten disease (INCL), EB-201 for epidermolysis bullosa, ABO-301 (AAV-FANCC) for Fanconi anemia disorder and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy for rare blood diseases. The Company also has a plasma-based protein therapy pipeline, including alpha-1 protease inhibitor (SDF Alpha) for inherited COPD, using its proprietary Salt Diafiltration ethanol-free process.

Industry

Biotechnology & Drugs

Contact Info

1330 Avenue of the Americas Fl 33

NEW YORK, NY

10019-5442

United States

+1.646.8134701

https://abeonatherapeutics.com/

Executive Leadership

Brian J. G. Pereira

Executive Chairman of the Board

Joao Siffert

Chief Executive Officer, Director

Edward Carr

Principal Financial Officer, Chief Accounting Officer, Vice President

Michael Amoroso

Senior Vice President, Chief Commercial Officer

Christine Berni Silverstein

Director

Key Stats

2.00 mean rating - 7 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.0K

2018

0.0K

2019

0.0K

2020(E)

0.0K
EPS (USD)

2017

-0.660

2018

-1.190

2019

-1.510

2020(E)

-1.034
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
1.80
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-74.80
Return on Equity (TTM)
-62.08

Latest News

Latest News

BRIEF-Abeona Therapeutics Reinitiates Enrollment In EB-101 Pivotal Phase 3 Viital™ Study In RDEB After Covid-19 Related Pause

* ABEONA THERAPEUTICS REINITIATES ENROLLMENT IN EB-101 PIVOTAL PHASE 3 VIITAL™ STUDY IN RDEB AFTER COVID-19 RELATED PAUSE AND ANNOUNCES PROGRESS IN PATIENT ENROLLMENT IN MPS III STUDIES Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Appoints Two New Independent Directors

* ABEONA THERAPEUTICS FURTHER STRENGTHENS BOARD WITH APPOINTMENT OF TWO NEW INDEPENDENT DIRECTORS Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Q1 Loss Per Share $0.52

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Calpers Urges Abeona Therapeutics Shareholders To Vote For Proposal Requesting Majority Vote For Director Elections

* CALPERS URGES ABEONA THERAPEUTICS SHAREHOLDERS TO VOTE FOR PROPOSAL REQUESTING MAJORITY VOTE FOR DIRECTOR ELECTIONS - SEC FILING

BRIEF-Abeona Therapeutics Executive Chair Executed Amends Separation Agreement

* ON MARCH 31, CO, STEVEN ROUHANDEH, EXECUTIVE CHAIRMAN EXECUTED AMENDMENT TO ROUHANDEH’S SEPARATION AGREEMENT WITH CO DATED JAN 2, 2020

BRIEF-Abeona Therapeutics Says Operations At Its Cleveland Manufacturing Facility Have Been Significantly Scaled Back

* ABEONA THERAPEUTICS - OPERATIONS AT OUR CLEVELAND MANUFACTURING FACILITY HAVE BEEN SIGNIFICANTLY SCALED BACK

BRIEF-Abeona Therapeutics Announces First Patient Treated In Pivotal Phase III Clinical Trial Evaluating EB-101 Gene Therapy

* ABEONA THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN PIVOTAL PHASE III CLINICAL TRIAL EVALUATING EB-101 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Announces First Patient Treated In Pivotal Phase Iii Clinical Trial Evaluating Eb-101 Gene Therapy For Recessive Dystrophic Epidermolysis Bullosa

* ABEONA THERAPEUTICS ANNOUNCES FIRST PATIENT TREATED IN PIVOTAL PHASE III CLINICAL TRIAL EVALUATING EB-101 GENE THERAPY FOR RECESSIVE DYSTROPHIC EPIDERMOLYSIS BULLOSA Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Q4 Loss Per Share $0.30

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER AND FULL YEAR 2019 FINANCIAL RESULTS AND BUSINESS UPDATES

BRIEF-Abeona Therapeutics Provides Clinical Update On MPS IIIA Gene Therapy Trial

* ABEONA THERAPEUTICS PROVIDES CLINICAL UPDATE ON MPS IIIA GENE THERAPY TRIAL AT THE 21ST ANNUAL ASGCT MEETING

BRIEF-Abeona Therapeutics Posts Q1 Loss Of $0.18 Per Share

* ABEONA THERAPEUTICS REPORTS FIRST QUARTER 2018 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Abeona Announces FDA Grants Rmat Designation To ABO-102 Gene Therapy In MPS Iiia

* ABEONA ANNOUNCES FDA GRANTS RMAT DESIGNATION TO ABO-102 GENE THERAPY IN MPS IIIA

BRIEF-Abeona Therapeutics Receives Orphan Drug Designation In The European Union For ABO-202 Gene Therapy Program In Batten Disease

* ABEONA THERAPEUTICS RECEIVES ORPHAN DRUG DESIGNATION IN THE EUROPEAN UNION FOR ABO-202 GENE THERAPY PROGRAM IN BATTEN DISEASE Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Appoints Carsten Thiel, Ph.D., As Chief Executive Officer

* ABEONA THERAPEUTICS APPOINTS CARSTEN THIEL, PH.D., AS CHIEF EXECUTIVE OFFICER

BRIEF-Abeona Therapeutics Appoints Carsten Thiel As Chief Executive Officer

* TIMOTHY J. MILLER WILL REMAIN PRESIDENT AND ASSUME POSITION OF CHIEF SCIENTIFIC OFFICER Source text for Eikon: Further company coverage:

BRIEF-Abeona Therapeutics Reports Q4 Loss Per Share $0.19

* ABEONA THERAPEUTICS REPORTS FOURTH QUARTER 2017 FINANCIAL RESULTS AND BUSINESS HIGHLIGHTS

BRIEF-Abeona Receives FDA Rare Pediatric Disease Designation For ABO-202 Gene Therapy Program In CLN1 Disease

* ABEONA THERAPEUTICS RECEIVES FDA RARE PEDIATRIC DISEASE DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN CLN1 DISEASE

BRIEF-Abeona Receives FDA Orphan Drug Status For Gene Therapy To Treat Rare Disease In Newborns

* ABEONA THERAPEUTICS RECEIVES FDA ORPHAN DRUG DESIGNATION FOR ABO-202 GENE THERAPY PROGRAM IN INFANTILE BATTEN DISEASE

BRIEF-Abeona Therapeutics Says Gene Therapy ABO-101 Is Well Tolerated

* ABEONA THERAPEUTICS REPORTS ON INITIAL SAFETY AND BIOPOTENCY SIGNALS IN MPS IIIB GENE THERAPY CLINICAL TRIAL

BRIEF-Abeona Receives FDA Regenerative Medicine Advanced Therapy Status For Experimental Gene Therapy For Rare Skin Disorder

* ABEONA RECEIVES FDA REGENERATIVE MEDICINE ADVANCED THERAPY DESIGNATION FOR EB-101 GENE THERAPY IN EPIDERMOLYSIS BULLOSA

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up